Journal article
Cannabidiol for at risk for psychosis youth: A randomized controlled trial
GP Amminger, A Lin, M Kerr, A Weller, J Spark, C Pugh, S O'Callaghan, M Berger, SR Clark, JG Scott, A Baker, I McGregor, D Cotter, Z Sarnyai, A Thompson, AR Yung, B O'Donoghue, E Killackey, C Mihalopoulos, HP Yuen Show all
Early Intervention in Psychiatry | WILEY | Published : 2022
DOI: 10.1111/eip.13182
Abstract
Background: No biological treatment has been firmly established for the at-risk stage of psychotic disorder. In this study we aim to test if subthreshold psychotic symptoms can be effectively treated with cannabidiol (CBD), a non-psychoactive compound of the plant Cannabis sativa. The question has taken on increased importance in the wake of evidence questioning both the need and efficacy of specific pharmacological interventions in the ultra-high risk (UHR) for psychosis group. Methods: Three-arm randomized controlled trial of 405 patients (135 per arm) aged 12–25 years who meet UHR for psychosis criteria. The study includes a 6-week lead-in phase during which 10% of UHR individuals are exp..
View full abstractRelated Projects (1)
Grants
Awarded by Wellcome Trust
Funding Acknowledgements
Wellcome Trust, Grant/Award Number: WT#216060/Z/19/Z